PE20110805A1 - Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso - Google Patents

Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso

Info

Publication number
PE20110805A1
PE20110805A1 PE2011000606A PE2011000606A PE20110805A1 PE 20110805 A1 PE20110805 A1 PE 20110805A1 PE 2011000606 A PE2011000606 A PE 2011000606A PE 2011000606 A PE2011000606 A PE 2011000606A PE 20110805 A1 PE20110805 A1 PE 20110805A1
Authority
PE
Peru
Prior art keywords
compounds
spiro
beta
secretases
modulators
Prior art date
Application number
PE2011000606A
Other languages
English (en)
Spanish (es)
Inventor
Ryan White
Albert Amegadzie
Marian C Bryan
Jian J Chen
Alan C Cheng
Thomas Dineen
Oleg Epstein
Vijay Keshav Gore
Zihao Hua
Jason B Human
Hongbing Huang
Charles Kreiman
Daniel La
Qingyian Liu
Vu Van Ma
Isaac Marx
Vinod F Patel
Wenyuan Qian
Matthew Weiss
Chester C Yuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20110805A1 publication Critical patent/PE20110805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PE2011000606A 2008-09-11 2009-09-11 Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso PE20110805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9608208P 2008-09-11 2008-09-11

Publications (1)

Publication Number Publication Date
PE20110805A1 true PE20110805A1 (es) 2011-11-09

Family

ID=41319591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000606A PE20110805A1 (es) 2008-09-11 2009-09-11 Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso

Country Status (21)

Country Link
US (1) US8426447B2 (enExample)
EP (1) EP2328903B1 (enExample)
JP (1) JP5579720B2 (enExample)
KR (1) KR20110073511A (enExample)
CN (1) CN102209721A (enExample)
AU (1) AU2009291602B2 (enExample)
BR (1) BRPI0918449A2 (enExample)
CA (1) CA2736130C (enExample)
CL (1) CL2011000516A1 (enExample)
CO (1) CO6362014A2 (enExample)
CR (1) CR20110134A (enExample)
EA (1) EA201100461A1 (enExample)
ES (1) ES2459195T3 (enExample)
IL (1) IL211440A0 (enExample)
MA (1) MA32705B1 (enExample)
MX (1) MX2011002705A (enExample)
MY (1) MY148558A (enExample)
PE (1) PE20110805A1 (enExample)
TW (1) TWI385175B (enExample)
WO (1) WO2010030954A1 (enExample)
ZA (1) ZA201102674B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
AU2011227501B9 (en) 2010-03-15 2013-08-22 Amgen Inc. Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use
WO2011130741A1 (en) * 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
WO2012027261A1 (en) 2010-08-23 2012-03-01 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
US20120157448A1 (en) * 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
CN103221407A (zh) 2010-11-22 2013-07-24 出光兴产株式会社 含氧稠环衍生物和含有其而成的有机电致发光元件
WO2012071279A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2013014007A (es) 2011-06-07 2014-03-12 Hoffmann La Roche [1,3] oxazinas.
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
HK1208817A1 (en) * 2012-05-30 2016-03-18 Comentis, Inc. Chromane compounds
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2014078314A1 (en) * 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
WO2016126721A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
DE102023106829A1 (de) 2023-03-19 2024-09-19 List Technology Ag Verfahren und Vorrichtung zur Behandlung eines Ausgangsproduktes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
US3185696A (en) * 1959-03-12 1965-05-25 Jack M Tien 3', 6'-diaminofluoran derivatives of gamma-lactam
FR2576178B1 (fr) 1985-01-24 1987-04-17 Furodet Philippe Procede de fabrication pour un enfumoir a chargement par-dessous
DE3601492A1 (de) 1986-01-20 1987-07-23 Vacuumschmelze Gmbh Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
KR20070013361A (ko) * 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
CA2453447A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
WO2003006013A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
US20030109559A1 (en) * 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
US7244755B2 (en) * 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
JP2005508940A (ja) 2001-10-05 2005-04-07 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なアリルアミド
US20050038019A1 (en) * 2001-10-29 2005-02-17 Beck James P. Hydroxy substituted amides for the treatment of alzheimer's disease
RS50504A (sr) * 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
AR037460A1 (es) * 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
MXPA04005428A (es) * 2001-12-06 2004-12-06 Elan Pharm Inc Hidroxietilaminas substituidas.
JP2005534614A (ja) * 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
CN1627944A (zh) * 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
DE60315664D1 (de) 2002-06-20 2007-09-27 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1562897B1 (en) * 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
AU2004204692B2 (en) * 2003-01-07 2009-07-09 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
EP1605940A1 (en) * 2003-03-14 2005-12-21 Merck Sharp & Dohme Ltd. METHOD FOR TREATING MILD COGNITIVE IMPAIRMENT AND FOR PREVENTING OR DELAYING ALZHEIMER’S DISEASE
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
MXPA05011150A (es) * 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
CA2522805A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
US7348448B2 (en) * 2003-07-01 2008-03-25 Merck & Co., Inc. Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CA2561267A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
ES2332659T3 (es) * 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
CN101103034A (zh) 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
CA2610828A1 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
AR054618A1 (es) 2005-06-14 2007-07-04 Schering Corp Compuestos de azetidina y su uso como inhibidores de proteasas
RU2008101667A (ru) * 2005-06-16 2009-07-27 Янссен Фармацевтика Н.В. (Be) Трициклические модуляторы опиоидов
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
US20070020316A1 (en) * 2005-07-13 2007-01-25 Raviv Laor Personal topical disinfectant device
US8211904B2 (en) 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP2612854B1 (en) * 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
EP2032542A2 (en) * 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
ATE538651T1 (de) 2006-10-30 2012-01-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
TW200902526A (en) * 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
ES2548774T3 (es) * 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
CA2712228C (en) * 2008-02-18 2013-04-16 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl amine derivatives
CL2009000954A1 (es) 2008-04-22 2010-12-31 Schering Corp Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras.
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
AU2009273324A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
CN102105475B (zh) * 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物

Also Published As

Publication number Publication date
CN102209721A (zh) 2011-10-05
IL211440A0 (en) 2011-05-31
US20100087429A1 (en) 2010-04-08
EP2328903A1 (en) 2011-06-08
MA32705B1 (fr) 2011-10-02
JP2012502112A (ja) 2012-01-26
EP2328903B1 (en) 2014-03-05
KR20110073511A (ko) 2011-06-29
MX2011002705A (es) 2011-09-09
ES2459195T3 (es) 2014-05-08
AU2009291602B2 (en) 2013-02-14
CR20110134A (es) 2011-08-04
CA2736130C (en) 2014-01-14
BRPI0918449A2 (pt) 2019-09-24
ZA201102674B (en) 2011-12-28
TW201022280A (en) 2010-06-16
CO6362014A2 (es) 2012-01-20
MY148558A (en) 2013-04-30
TWI385175B (zh) 2013-02-11
CL2011000516A1 (es) 2011-08-26
WO2010030954A1 (en) 2010-03-18
JP5579720B2 (ja) 2014-08-27
EA201100461A1 (ru) 2011-10-31
CA2736130A1 (en) 2010-03-18
US8426447B2 (en) 2013-04-23
AU2009291602A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
AR084507A1 (es) Derivados de indazoliltriazol
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20110383A1 (es) Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
PE20130395A1 (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
UY32303A (es) Tiolactamas y sus usos
ECSP10010722A (es) Compuestos orgánicos
AR085903A1 (es) Compuestos de pirazol sustituidos con halogeno
CL2011000516A1 (es) Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer.
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
MX2011007663A (es) Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2.
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
PE20140934A1 (es) Derivados de pirazol
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos

Legal Events

Date Code Title Description
FD Application declared void or lapsed